Trial Profile

A Phase 1 clinical trial evaluating single ascending doses and multiple ascending doses of ATI-052

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 29 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BSI 502 (Primary)
Indications Autoimmune disorders; Respiration disorders; Skin disorders
Focus Adverse reactions; Proof of concept

Most Recent Events

22 Apr 2025 According to Aclaris Therapeutics media release, Company expects to initiate the trial in the second quarter of 2025.
22 Apr 2025 According to Aclaris Therapeutics media release, the U.S. Food and Drug Administration (FDA) has cleared IND application for this study.
04 Mar 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com